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Who 's afraid of the recent biomedical heritage? 
Medicine is one of the oldest and most venerated ingredients of the world's cultural 
and scientific heritage. Consequently medical artefacts feature prominently in many 
university museum collections . With respect to the historical time range covered, 
however, almost all museums deal with what might be called 'modem medicine', that 
is, they mainly contain artefacts and ideas that represent the medical practices of the 
modem era, from seventeenth century anatomical specimens to late-twentieth century 
mechanical medical instruments. With few exceptions, museums have not yet taken the 
rapidly growing biomedical culture of our present age into account, and so far no mu­
seum has made systematic efforts to document the recent biomedical heritage". 
I suggest it is time for university museums to take biomedicine - that is, the fusion 
of ceil biology, molecular biology and information technology with clinical diagnostics 
and therapeutics - seriously3. The reason is, of course, that biomedicine is emerging as 
a significant formative part of contemporary society and culture. The discovery of the 
structure of DNA in 1953 and the subsequent rise of molecular biology have radically 
changed the research agendas, strategic decisions, and curricula of medical faculties 
over the last decades. A rapidly growing number of new molecular technologies have 
changed diagnostic and therapeutic methods beyond recognition; today's clinical bio­
chemical laboratory is a highly sophisticated and robotized molecular diagnostic sys­
tem and gene therapy is becoming clinical reality. Digitalization too has changed bio­
medical research and clinical practices drastically in the last decades. Medical research 
is highly dependent on computerized methods. Clinical departments like neonatal 
1 K. Arnold, Time heals: making history in medical museums [in:] G. Kavanagh (ed.), Making Histories 
in Museums, Leicester University Press, London 1996, p. 15-29. 
2 A notable exception is Science Museum, London, which has devoted the major part of a whole new 
extension, The Wellcome Wing, to exhibitions of recent biomedicine (see http://www.sciencemuseum. 
org.uk/wellcome-wing/splash_ie.html). 
3 'Biomedicine' as defined here excludes nursing, social medicine, classical epidemiology, social psy­
chiatry, etc. 'Recent' is defined as the period covering the professional life of historical biomedical actors 
that are presently living, i.e., approx. the last 50 years. 
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wards or intensive care units are as digitalized as the cockpit in a modern aircraft. Di-
agnostic imaging fools like CT-, MR- and PET-scarming would be impossible without 
advanced digital technology. 
This combined process of molecularization and digitalization of the laboratory and 
the clinic (in other words, biomedicalization)4 is embedded in a broader social and 
cultural context. The many (and often politically mediated) interactions between the 
transnational 'biomedical-industrial complex' and the steadily growing popular de-
mand for better health care are turning biomedicine into a significant player on the 
global economic arena5. Biomedicine has also entered the political scene. While some 
view its recent developments as a threat to basic human values, others see it as a key to 
the future of humankind. New technologies such as stem cell manipulation, cloning, 
and tissue engineering have raised both professional and popular expectations of the 
powers of biomedicine to combat, for example, cancer and degenerative diseases. 
How can university museums accommodate to these material and discursive 
changes in the medical landscape? What consequences will the recent revolution in 
biomedical research and clinical development have for medical history collections and 
exhibitions? In the Medical Museion at the University of Copenhagen we are presently 
trying to resolve these and similar questions6. In this paper I will discuss one of the 
museological problems raised, viz., how to handle the abstract and non-tangible char-
acter of many recent biomedical objects. 
The Medical Museion is the continuation of the Medical History Museum in Co-
penhagen, founded by a private initiative in 1906. The rapidly expanding collections 
were taken over by the university in 1918, and thirty years later they were moved to 
their present location in the former Royal Academy of Surgeons and adjacent build-
ings. Today the University of Copenhagen owns one of the largest and most diversified 
medical history university collections in the world, including thousands of obstetric 
radiological, ophthamological, dental, and surgical instruments, several complete 
apothecaries and old pharmaceutical laboratories, an interesting assortment of micro-
scopes, and a world-famous osteopathological collection from medieval leprosaria 
Altogether the collections comprise approx. 60.000 registration units (a registration 
unit may contain many separate physical items so the number of individual obiects 
probably exceeds a hundred thousand); in addition there are close to 100 000 
iconographical items, a library of 30.000 volumes, and approx. 4000 archival units 
including hospital patient records from the late eighteenth century and onwards Only 
a small proportion of this material is displayed in the public exhibitions; most is kept in 
storage or m special 'study collections' for specialists 
tie* rf L m M S t H 0 t h fu m ! d i C i U n i V e r S i t y m U S C U m S ' t h e c o l l e c t i n g a n d e x I « i o n activi-
ties of the Medical History Museum were focused on 'modern medicine' especially on 
instruments that documented the triumph of the modem medical profTssioX the late 
4 For an analysis of biomedicalization, see A.E Clarke J K 9h,m T U . r D c , 
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nineteenth and first half of the twentieth century. But in recent years the museum has 
changed its orientation. The incentive for this move was the fact that the museum had 
stagnated since the 1970s; there were no research activities of any significance, the 
collections were run by amateur curators, and the exhibitions had not been revised for 
decades. A devastating report by The Danish State Board of Museums in 2000 raised 
negative headlines ('Chaos in the museum') in the Danish medical weekly7, and in-
duced the Faculty of Health Sciences to take its responsibility as owner. A year earlier, 
the chair in history of medicine had been filled to boost medical history research; in the 
following years three new museum positions were announced. Basic funding was in-
creased as well, and in 2003 the faculty gave its unanimous support to a five-year plan 
for re-conceptualizing the former Medical-History Museum as a Medical Museion. 
The Medical Museion concept is two-pronged. The basic idea is that research, 
teaching, collection activities and public outreach (including exhibitions) are closely 
integrated activities that mutually support each other. The classical notion of 'museion' 
has been chosen to symbolize the bridging of the gap between a traditional academic 
medical history research and teaching culture focusing on the production of texts (arti-
cles, books), and a traditional curatorial culture dealing with the acquisition, preserva-
tion and exhibition of material objects and images. In daily practice, this bridging 
means that both research and museum staff attend the weekly seminar dealing with all 
aspects of the institution, from registration systems and conservation methods to the 
history and philosophy of biology and the interaction between biomedicine and art; 
guest speakers include medical researchers, historians, ethnologists, museologists and 
artists. In other words, instead of making the traditional distinction between an aca-
demic university department and a museum, research, curating and acquisition are 
considered to be closely related forms of 'inquiry', and scholarly publishing, teaching 
and exhibitions are seen as closely related aspects of'presentation'. 
The other main idea behind the Medical Museion concept is to shift the focus to the 
understanding, documentation and presentation of recent biomedicine in its social and 
cultural context. From the point of view of our university identity this shift of focus is 
advantageous as a growing number of conferences, monographs and research articles 
on different aspects of biomedicalization have appeared in the last decade. In other 
words, we are joining a growing trend among historians of science, historians of medi-
cine, and scholars of science studies to investigate the recent history of biomedicine. 
From the point of view of our museum identity, however, the new focus on recent 
biomedicine does raise some problems. With the exception of the Science Museum in 
London, very few museum institutions have taken the recent biomedical revolution 
seriously, and even fewer have begun to systematically acquire biomedical artefacts. 
Most medical history exhibitions still present medicine as it were in the period from the 
late eighteenth to the mid-twentieth centuries, that is, before molecular biology and 
information technologies began to change its face. 
However, if (or rather when) museums begin to pay attention to recent biomedicine, 
they will be running into a major museological problem. This problem has to do with 
the object character of biomedical artefacts. Traditionally, museums are institutions 
that deal with material objects and material culture. The key-word here is tangibility -
7 J. Haller, Kaos pa museet: vi kan skabe et unikt museum, „Ugeskrift for Lseger", 2001, vol. 163, 
p. 2158-2161. 
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and medical museums are no exceptions, filled as they are with surgical instruments, 
microscopes, contraceptive devices, iron lungs, hospital beds, anatomical specimens, 
and so forth. Medical museum curators usually do not consider it a problem to define 
what an 'object' is, or what constitutes a 'good' museum object. Good objects are con-
crete, sensual and spectacular, like foot-driven dentist's drills, Siamese twins in jars, 
amputation saws, and trepanation instruments in handy travel sets. These and similar 
objects are considered 'good' objects because they are made of easily recognizable 
materials and resemble familiar tools; they are immediately understandable and also 
appeal to our fear of pain and death; they trigger the visitor's attention, elicit memories, 
evoke emotions, and make us pause in front of the objects with a sense of curiosity and 
wonder. The lithoclast - an instrument invented in the early nineteenth century to crush 
bladder stones through the urethra (thus lowering the risk and pain of classical stone 
cutting) - is an archetypically 'good' medical history exhibition object. Young male 
visitors to the Medical Museion regularly turn pale when they realize how the instru-
ment was used - before anaesthesia. 
The emergence of recent biomedicine, however, challenges this classical notion of 
material objects as familiar, tangible, and sensuous. Today's biomedical objects are 
neither familiar, nor tangible; neither sensuous, nor emotionally evocative. To illustrate 
the challenges of recent biomedicine to university museums, I will shortly discuss three 
cases: DNA microarray analysis, PET scanning, and molecular therapy. 
Microarray analysis is one of the most sophisticated methods in post-genomic 
medicine. Based on the fact that the degree of hybridization between single-stranded 
oligonucleotide molecules is a measure of their similarity, it uses arrays of hundreds of 
thousands of specific oligonucleotide sequences as probes to map an unknown 
RNA/DNA-sample; this makes it possible to gauge the gene expression level of the 
entire genome (that is, which genes are 'on' and which are 'off) in one single run. The 
analytical power of the method has ushered a rapid growth of expectations in the bio-
medical research community and the pharmaceutical industry to use it as a major diag-
nostic and therapeutic tool, for example for individualized drug treatment: 'The explo-
sion in interest in DNA microarrays has almost been like a gold rush', proclaims 
a textbook in the field8. 
The most widely used and best known microarray platform, the Affymetrix 
GeneChip®, was invented in the late 1980s and came into industrial production a few 
years later . By combining information technology and molecular biology the 
GeneChip embodies the very essence of biomedicine. It illustrates the restructuring of 
health-care in the advanced post-industrial societies towards increased individualisa-
tion of diagnostics and treatment. Also, by drawing on globally produced and globally 
available sequence data bases it epitomizes another salient aspect of the biomedical 
revolution, viz., its integration in the process of globalization. Furthermore, as one of 
the few biomedical technologies that has made it to the front-page of Financial Times, 
the GeneChip is an example of how cutting-edge university research often has given 
rise to successful private enterprises (the 'Silicon Valley effect') over the last decades. 
Finally it reminds us of Peter Sloterdijk's point that biotechnology, for better or for 
S. Knudsen, Guide to Analysis of DNA Microarray Data, Wiley, 2nd ed., New York, 2004, p. 2. 
9 For Affymetrix' own historiography, see ht1p://www.affymetrix.corn/support/technical/other/pioneer 
brochure.pdf 
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worse, can make the old vision of eugenics come true10. The Affymetrix GeneChip 
thus provides an ample focusing point for historians of recent biomedicine and bio-
technology. 
For museums curators, however, the GeneChip poses a problem. What is immedi-
ately available for display is just the handy 1 x 2 inch plastic casing where the hybridi-
zation reaction takes place. The Vz x Vi inch 'chip' inside, with some half million oligo-
nucleotide molecular-sized probes attached to it, is not immediately visible, or intelli-
gible. The result of the test is only visible indirectly; the genome data are produced by 
reading the hybridization pattern on the chip with a laser scanner (which looks like an 
advanced coffee machine) and the result is interpreted by a computer program. It is 
hardly necessary to say that the GeneChip technology, which is now revolutionizing 
medical diagnostics, makes poor museum objects because all the components of the 
platform are abstract, intangible and hardly evoke any memories or strong emotional 
reactions. 
The PET (positron emission tomography) scanner, too, illustrates the problem of 
displaying new biomedical artefacts in a museum exhibition. The instrument is built to 
produce images representing the inner metabolism of the body; information that is 
indeed useful for diagnostic purposes. The patient is injected with glucose molecules 
marked with a short-lived isotope that emits positrons that can be measured by 
a detector. The ensuing data are then interpreted by a computer program to represent 
slices (tomography) of the spatial distribution of glucose metabolism in the body on 
a screen. For example, the screen image of metabolism in the brain of patients with 
Alzheimer's disease is significantly different from that in 'normal' patient brains. 
The PET scanner is an impressive piece of combined digital and molecular techno-
logy which has already had great impact on medical diagnostics. An update of earlier 
imaging technologies, like X-ray, as it were - and as such it is a 'must' in any museum 
that wishes to document and exhibit significant features of recent university medicine. 
But whereas X-ray technology is relatively easily understood in terms of 'modem 
medicine' and does not create any problems for medical museum curators, the PET 
scanner poses at least two museological problems. 
One problem is that the PET scanner defies traditional museological display strate-
gies. The directly visible and tangible 'objects' - the enclosing cabinet and the bed 
which the patient is placed on during the scanning procedure - are not at all important 
for the functionality of the scanner. The working material parts are either invisible and 
non-tangible (the isotope molecules) or non-intelligible (the detector and the computer 
hardware) and in addition do not make much sense without the resulting screen image. 
The 'image' in turn is indeed visible as long as the machine runs, but it is not tangible; 
it is the ephemeral result of the handling of signal data by the 'text' (that is, the com-
puter programme code). The other problem (and this is why I have placed the words 
'object', 'image' and 'text' between inverted commas) is that the PET scanner blurs the 
traditional categories of 'object', 'image' and 'text'. How shall this artefact be classi-
fied? Does it belong among the physical museum objects? Or is it better placed (as an 
image) in the iconographical collection? Or even (as program code) in the archive? 
My last example of how recent biomedicine is a challenge to university museums is 
the advent of molecular therapy. Traditionally, pharmacology is based on trial-and-
10 P. Sloterdijk, Regelnfur den Menschenpark, SuhrkampVerlag, Frankfurt am Main, 1999. 
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-emir experience. The administered drug may not even be chemically characterized (as 
in folk herbal medicine) and physicians usually have no knowledge of the biochemical 
mechanism behind the effect; it just happens to work. Now, however, the biochemical 
mechanism that mediates between the active substance and the physiological response 
is being elucidated in a growing number of cases. A good example of molecular ther-
apy is AstraZeneca's Losec®, the world's best-selling drug against ulcer and heart-
bum in the 1990s. Earlier, ulcer patients were often treated with surgery; today they are 
given antibiotics against the Heliobacter infection and Losec to lower stomach acidity 
(often in the form of combination therapy). 
The active substance in Losec is a synthetic molecule, omeprazol, that specifically 
blocks the proton pump and hence acid production in the stomach. In other words, the 
omeprazol molecules work as a kind of specific biochemical microsurgery. It is thus 
a smart medical technology (and a major source of income for AstraZeneca) - but it is 
hardly a best-seller for medical museums. True, the Losec pill is tangible, but it looks 
very much like all other pills. The trillions of 'molecular knives' (omeprazol mole-
cules) are intangible and invisible. The ion channels in the gastric lining are tangible on 
the microscopic level, but not visible to the naked eye. Furthermore, the most interest-
ing 'object' is neither the pill nor the molecule, but the international network of scien-
tists, medical doctors, advertising firms, and financial analysts who made a business 
success out of the omeprazol molecule. One could, of course, put the pill on a piece of 
black cloth under a spotlight and play a recorded deep voice telling the visitor that it 
gave AstraZeneca a 8 billion dollar revenue in the year 2000 only. But such stories are 
probably better told in books and magazines than in exhibitions. Likewise, the mo-
lecular and biological mechanisms of omeprazol may be better told in book pages and 
computer screens than in museums. 
Microarray systems, PET scanners, and molecular therapies exemplify the problems 
involved in collecting and exhibiting recent biomedicine. Consequently I believe that 
medical museums today are caught in a paradox. On the one hand, biomedical research 
and technology fills more and more of our lives. On the other hand, the whole idea of 
what constitutes a medical museum collection and what is displayable in a medical 
museum exhibition is open to question, because medical diagnostics and treatment has 
become less visible and less sensuous. The biomedical ideas and artefacts of the last 
decades are very different from those presently gathered and displayed in museums. 
They are smaller (often microscopic), more abstract and mediated, less tangible (if not 
altogether intangible), and generally much less emotionally evocative than traditional 
'modern medical' objects. And sometimes they are not even material artefacts in the 
classical sense, but 'boundary artefacts'11, that is simultaneously 'material objects' 
texts' and 'images', depending on the context of interpretation. 
There may come a point when it becomes impossible to display such objects in 
a museum exhibition in any meaningful way. After all, who would come to the local 
university museum on a Sunday afternoon to read computer manuals, look at anony-
mous instrument plastic cabinets discretely labelled Perkin-Elmer or Hewlett-Packard 
or watch video screens that represent repetitive patterns of DNA hybridization reac-
•trl^Zfb^Ztn1 Tt*? a d°P t e d f r°m SX- Star and I R- Griesemer ' ^titutional ecology, 
Z ^ m i ^ T t Z t T ' ' f?ateUri andpr°fessionals in BerkeleyS Museum of Vertebrae 
zoology. IW/-1939, „Social Studies of Science", 1989, vol. 19, p. 387-420. 
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tions? Will not those who are curious about the emergence of recent biomedicine and 
its impact on the world rather download the molecular images on their own computer 
or read about the global biomedical economy on a webpage or in a book or a magazine 
article instead? It makes sense to visit the local university museum to see lithoclasts, 
amputation saws, and Siamese twins in jars. But why at all visit a museum if one wants 
to watch displays which elicudate the basic textbook principles of a PET scanner, 
a gene microarray or a 'molecular knife'? 
I believe this is a genuine museological problem and one that all museums with 
medical collections and exhibitions will have to solve in the near future - unless they 
want to restrict their activities to the safe realm of 'modern medicine'. I am not pre­
tending that the Medical Museion in Copenhagen has a solution in sight or even 
a smart way of circumventing it. But we are presently working on explicating and con­
ceptualizing the problem, and with some help from our colleagues in the university 
museum world we will hopefully together be able to find solutions in the future. 
STRESZCZENIE 
Kto się obawia najnowszego dziedzictwa biomedycznego? 
Ponieważ biomedycyna - fuzja biologii komórkowej, biologii molekularnej oraz infor­
matyki z diagnostyką i terapeutyką kliniczną - staje się znaczącą częścią współczesnego 
społeczeństwa i kultury, czas, by muzea uniwersyteckie poważnie zaczęły traktować tę 
dyscyplinę nauki. Muzeum Medyczne przy Uniwersytecie w Kopenhadze stara się obecnie 
rozwiązać problemy muzealne związane z przedstawieniem najnowszych artefaktów bio­
medycznych. Tradycyjnie muzea zajmują się wymiernymi obiektami materialnymi: dobre 
artefakty muzeum medycznego są konkretne, spektakularne i działające na zmysły, a także 
łatwo zrozumiałe; przywołują wspomnienia i wywołują emocje. Jednakże pojawienie się 
biomedycyny zmienia klasyczne pojęcie eksponatów muzealnych jako przede wszystkim 
wymiernych i pojmowanych zmysłami. Dzisiejsze obiekty biomedyczne są abstrakcyjne, 
niematerialne i trudne do zrozumienia; przywołują one niewiele wspomnień i nie wywołują 
żadnych emocji. Wyzwania stawiane przez biomedycynę muzeom uniwersyteckim przed­
stawiono w odniesieniu do trzech przykładów: analizy układu DNA, obrazowania pozytro-
nowego PET oraz terapii molekularnej. Niniejsza praca stawia wniosek, iż obecnie muzea 
medyczne są ofiarą paradoksu. Z jednej strony badania biomedyczne i technologia coraz 
bardziej wypełniają nasze życie, od opieki nad noworodkami do oddziałów intensywnej 
opieki dla osób nieuleczalnie chorych. Z drugiej strony, zaczyna być problematyczne uka­
zanie tego, co jest ideą muzeum historii medycyny, z przedstawieniem jego kolekcji 
w sposób, który byłby zarazem ekspozycyjny, jak i łatwo zrozumiały dla publiczności. 
II. I. The lithoclast, designed by Ludvig Levin Jacobsen (1783-1843), is a typical tangible object which 
provokes the museum visitor's emotions. It was inserted through the urethra (without anaesthesia) to 
crush bladder stones (courtesy Medical Museion, University of Copenhagen) 
II. II. The GeneChip® is an icon of high tech biomedicine and an example of the intangible character of 
recent biomedical objects. This Human Genome U133A array from Affymetrix which can analyze the 
expression level of 14.500 well-characterized human gens in one single run hardly raises any emotions 
in visitors (courtesy Medical Museion, University of Copenhagen) 
